In my role as Laboratory Operations Manager at QuantuMDx, I am responsible for managing our suite of laboratories and Health and Safety. The safety and wellbeing of our staff is a priority at QuantuMDx and I have a multi-disciplined team of Representatives of Employee...
The Big Catch-Up World Immunisation Week aims to raise awareness of vaccine-preventable diseases and encourage collaborative action to strengthen immunisation programmes and protect against disease throughout all stages of life. The theme for 2023 is ‘The Big...
If the past three years have taught QuantuMDx anything, it would be to prepare for the unexpected. While it can be difficult to predict which infectious disease will emerge as ‘the next big thing’, surveillance tools map the occurrence and transmission of certain...
International Day of Women & Girls in Science supports full and equal access to and participation in science for Women and Girls along with gender equality and female empowerment. QuantuMDx have conducted interviews with women holding scientific roles across...
Human papillomavirus (HPV) is the leading cause of cervical cancer. In this short post, which coincides with Cervical Cancer Prevention Week (23-29 January 2023), find out more about how HPV can cause cancer, the significance of different HPV subtypes in the...
NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay, has been approved for sale in the UK under The Medical Devices (Coronavirus Test Device Approvals) (Amendment)...
SARS-CoV-2, the causative agent of COVID-19, and influenza are two well-known respiratory viruses, but what do you know about RSV (Respiratory Syncytial Virus)? Here, Carolyne Horner, Medical Scientific Liaison, describes aspects of RSV acute respiratory infection...
Preventing Antimicrobial Resistance Together Antimicrobial resistance (AMR) describes the situation when microorganisms (bacteria, fungi, parasites and viruses) no longer respond to the drugs (antimicrobials) that are used to treat infections. As a consequence,...
Agreement will initially cover the UK and France with potential to expand to other European countries and worldwide NEWCASTLE UPON TYNE, UK, 2 November 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point of Care molecular...
The agreement sets a roadmap for the commercialisation of Q-POC™ and its assays in China The two companies will collaborate to accelerate the development of new assays on the Q-POC™ platform Offers potential for component sourcing and manufacturing optimisation...
This article has been guest written by our CFO, Martin Walton. We have all recently witnessed at very close quarters the fact that not only has SARS-COV-2 not gone away, but it is also very much in the ascendant again. Many people have been laid low in recent weeks -...
Diagnosing, treating and managing respiratory infections NEWCASTLE UPON TYNE, UK, 5 July 2022. QuantuMDx Group Limited (“QuantuMDx”) will be offering insights and advice on tackling respiratory infections in the wake of the pandemic during a webinar later this month....
NEWCASTLE UPON TYNE, UK, [17 June 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point of Care diagnostics, is pleased to announce that Q-POC™ has made the SelectScientists’ Choice Awards shortlist for the Best New Clinical...
NEWCASTLE UPON TYNE, UK, 14 June 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point-of-Need diagnostics, is pleased to announce that its Co-Founder and former CEO Elaine Warburton OBE, has been recognised as one of the top 50...
NEWCASTLE UPON TYNE, UK, [9] June 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational point-of-care diagnostics, is pleased to announce that it has won the Special Recognition Award (Response to Covid-19)] at the Med-Tech Innovation...
New multiplex panel can detect SARS-CoV-2, Flu A, Flu B & RSV at the Point of Care Accurate PCR results delivered in approximately 30 minutes NEWCASTLE UPON TYNE, UK, 26 May 2022. QuantuMDx Group Limited (‘QuantuMDx’ or the ‘Company’), a UK-based...
NEWCASTLE UPON TYNE, UK, [13] May 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce that it has won the Innovation Award at the Medilink Healthcare Business Awards 2022. The Innovation Award was awarded to the Company’s Q-POC™ platform, recognising...
For the first time in three years, it appears we can look forward to a summer where we might feel more relaxed about respiratory viruses. Nonetheless, healthcare services are bracing themselves for what might be an extremely challenging autumn and winter. After two...
NEWCASTLE UPON TYNE, UK, 29 APRIL 2022. QuantuMDx Group Limited (“QuantuMDx”), is thrilled to announce the launch of a new website www.quantumdx.com/. Our new website features improved functionalities and easy access to essential information about our solution and our...
NEWCASTLE UPON TYNE, UK, 01 APRIL 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce that it has won two Bionow Awards 2021, which took place last night, Thursday 31 March 2022. The company was shortlisted for three awards, winning two in total. The...
NEWCASTLE UPON TYNE, UK, 25 MARCH 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce that it has won the Medical Life Sciences award at the Made in North East Awards 2022. The Made in North East Awards applaud quality products and services that...
NEWCASTLE UPON TYNE, UK, 10 MARCH 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its SARS-CoV-2 RT -PCR detection assay, has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals)...
NEWCASTLE UPON TYNE, UK, 24 FEBRUARY 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce the appointment of Martin Walton as Chief Financial Officer. Martin has over 35 years’ experience working within large global companies with the last 15...
NEWCASTLE UPON TYNE, UK, 22 FEBRUARY 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its rapid PCR SARS-CoV-2 test, with the multiplex Q-POC™ platform, has been approved for continued sales in the UK under the UK Health Security Agency’s Medical...
The last few years have felt long and have been difficult for most of us, thanks in no small part to the COVID-19 pandemic. Although it is beginning to feel like we’re through the worst of it, many people are acutely aware of the continuing risks to vulnerable people...
Last week QuantuMDx achieved yet another milestone by introducing Laboratory Information System (LIS) connectivity to the Q-POC™ software. The latest software release for the Q-POC™ platform, 3.2, is a significant upgrade that enables test records to be...
We recently conducted a survey of how the demands of COVID-19 testing had impacted on UK care homes together with Care Home Professional magazine. What we found was shocking: the demands of COVID-19 testing has pushed homes to breaking point. Many staff told us...
NEWCASTLE UPON TYNE, UK, 26 NOVEMBER 2021. QuantuMDx Group Limited (“QuantuMDx”), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC™, as well as its future respiratory panel (SARS-CoV-2, Flu A, Flu B and RSV A/B),...
Funds will be used to develop further multiplexing capabilities and menu expansion in collaboration with Sansure, on the Q-POC™ platform Cooperation Agreement to accelerate regional commercialisation of Q-POC™ and its cassettes in China and other South-East Asian...
Providing a rapid, PCR COVID-19 testing solution to the UK film & TV industry NEWCASTLE UPON TYNE, UK, 16 August 2021. QuantuMDx has announced it is partnering with Cignpost Diagnostics, (‘Cignpost’), a leading provider of COVID-19 workplace testing to the...
NEWCASTLE UPON TYNE, UK: QuantuMDx today announces the launch of Q-POC™ - a rapid, PCR point of care diagnostic system. Launching at ECCMID 2021, QuantuMDx’ Q-POC™ system and its first test, a SARS-CoV-2 detection assay, are now CE-IVD marked under the In Vitro...
Diagnostic Goods and Services (Lot 1) Research and Development Goods (Lot 2) NEWCASTLE UPON TYNE, UK, 08 June 2021. QuantuMDx has been successful in both Public Health England (‘PHE’) tenders the Company applied for. QuantuMDx will be included in the Framework...
NEWCASTLE UPON TYNE, UK, 26 May 2021. QuantuMDx has appointed Mirre de Noo, as a Non-Executive Director. Mirre has over 20 years of experience in healthcare, strategy and innovation. As a life sciences and healthcare executive she has a track record of introducing and...
NEWCASTLE UPON TYNE, UK, 24th March 2021. QuantuMDx today announces it has raised £11 million in its latest funding round. Proceeds will be used to complete manufacturing and commercial scale up of Q-POC™, QuantuMDx’s rapid, PCR point of care diagnostic system...
NEWCASTLE UPON TYNE, UK, 13 February 2021. QuantuMDx today welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of its purpose-built HQ in Newcastle upon Tyne. QuantuMDx has developed Q-POC™ a revolutionary 30 minute PCR diagnostics device,...
Andy Whittle, VP Manufacturing at QuantuMDx, discusses the highs and lows of scaling up to manufacture, during a global pandemic. What is your background? I've over 20 years manufacturing experience, focusing primarily within life science and medical devices. I...
Sam Bhatt is a Programme Manager at QuantuMDx. Here, Sam tells us more about himself and gives us an insight into his role. When did you start working at QuantuMDx? I joined the QuantuMDx team in May 2015, not long after I completed my PhD (in radiotracers for...